Resistance to Tyrosine Kinase Inhibitors
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The vo
- PDF / 3,503,871 Bytes
- 194 Pages / 439.42 x 683.15 pts Page_size
- 28 Downloads / 203 Views
Daniele Focosi Editor
Resistance to Tyrosine Kinase Inhibitors
Resistance to Targeted Anti-Cancer Therapeutics Volume 10
Series Editor Benjamin Bonavida
More information about this series at http://www.springer.com/series/11727
Daniele Focosi Editor
Resistance to Tyrosine Kinase Inhibitors
Editor Daniele Focosi Pisa University Hospital Pisa, Italy
ISSN 2196-5501 ISSN 2196-551X (electronic) Resistance to Targeted Anti-Cancer Therapeutics ISBN 978-3-319-46090-1 ISBN 978-3-319-46091-8 (eBook) DOI 10.1007/978-3-319-46091-8 Library of Congress Control Number: 2016957745 © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
To my wife Emona and my children Enea and Anna
Preface
To reduce the adverse effects of chemotherapy agents, various targeted cancer therapies have been developed. Target-based cancer therapy has revolutionized cancer treatment, and several agents have shown more specific effects on tumor cells than chemotherapies. Small molecule inhibitors and monoclonal antibodies are specific agents that mostly target tumor cells but have few side effects on normal cells. Although these agents have been very useful for cancer treatment, however, the presence of natural and acquired resistance has often blunted the potential of targeted therapies. A better understanding of tumor cell resistance mechanisms to current treatment agents may provide an appropriate platform for developing and improving new treatment modalities. Tyrosine kinases represent one of the commonest and most important enzyme classes in the cell physiome. Tyrosine kinases on the cell surface often act as receptors for important intercellular mediators, while intracellular tyrosine kinases are fundamental mediators of signal transduction from receptors to effec
Data Loading...
